监管干预限制肾素-血管紧张素系统阻滞剂联合使用的效果:丹麦全国药物利用研究
本研究评估欧洲药品管理局2014年限制肾素-血管紧张素系统(RAS)阻滞剂联合使用的风险最小化措施在丹麦的效果。结果显示RAS阻滞剂联合配药率从0.01%降至0.0003%,干预后每百万人群联合配药额外减少0.45(95%CI -0.66至-0.25),总体上干预对联合使用影响甚微,但联合使用率已很低,丹麦现阶段可能无需进一步干预。
要点
- RAS阻滞剂联合配药率从0.01%降至0.0003%。
- 干预后每百万人群联合配药额外减少0.45(95%CI -0.66至-0.25)。
- 总体上监管干预对RAS阻滞剂联合使用影响微小。
核心结论
- 欧洲药品管理局2014年限制RAS阻滞剂联合使用的措施在丹麦总体上对联合使用影响甚微。
- 鉴于丹麦RAS阻滞剂联合使用率已很低,现阶段可能无需进一步干预限制其联合使用。
研究设计与样本
- 采用自回归积分滑动平均中断时间序列回归评估配药趋势。
主要发现
- RAS阻滞剂联合配药率从0.01%降至0.0003%。
- 干预前趋势已在下降,干预后每百万人群联合配药额外减少0.45(95%CI -0.66至-0.25)。
关键数值与推荐
- 联合配药率由0.01%降至0.0003%。
- 干预后每百万人群联合配药额外减少0.45(95%CI -0.66至-0.25)。
临床怎么用
- 临床药师应知晓RAS阻滞剂联合使用风险及监管限制,该干预在丹麦未显著改变已很低的联合使用率。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
This study aimed to evaluate the impact of the risk minimisation measures issued by the European Medicines Agency in 2014 to restrict the combined use of renin-angiotensin system (RAS) blocking agents in Denmark. Data from the Danish National Prescription Registry covering all medications dispensed during January 2008-December 2018 was used. The outcome was monthly prevalence of patients codispensed RAS blockers. Autoregressive integrated moving average interrupted time series regression was used to evaluate dispensing trends. The prevalence of patients codispensed RAS blockers decreased from 0.01 to 0.0003%. Preintervention trend was declining and further decreased with an additional -0.45 (95% confidence interval -0.66, -0.25) codispensing per million population after the intervention. Overall, the intervention had minimal impact on the combined use of RAS blockers. However, as the combined use of RAS blockers is low, further interventions to restrict the combined use of RAS blockers may not be required in Denmark at this point.
引用
- Sindahl P, Ofori-Asenso R, Hallgreen CE, et al. Impact of regulatory interventions to restrict the combined use of renin-angiotensin system blockers: A Danish nationwide drug utilisation study. Br J Clin Pharmacol. 2021. PMID: 34519065. doi:10.1111/bcp.15080
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。